Key Points
- Evolus insider David Moatazedi sold 105,108 shares at an average price of $9.04, generating approximately $950,176. Following the transaction, his stake declined 17.38% to 499,592 shares.
- Evolus shares opened at $9.30, near their 52-week high of $9.31, with a market capitalization of approximately $614 million. The stock has risen significantly from its 52-week low of $3.86.
- Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $14.50; institutional investors own 90.69% of the company.
Evolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 105,108 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the sale, the insider directly owned 499,592 shares of the company's stock, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Evolus Stock Up 2.8%
Shares of EOLS stock opened at $9.30 on Friday. The stock has a market cap of $614.26 million, a price-to-earnings ratio of -17.88 and a beta of 1.42. Evolus, Inc. has a fifty-two week low of $3.86 and a fifty-two week high of $9.31. The firm's 50 day moving average price is $7.26 and its two-hundred day moving average price is $6.08.
Wall Street Analysts Forecast Growth
EOLS has been the topic of several recent research reports. Wall Street Zen upgraded shares of Evolus from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Weiss Ratings upgraded Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, June 15th. HC Wainwright reissued a "buy" rating and set a $13.00 price objective on shares of Evolus in a report on Tuesday, August 25th. Finally, BTIG Research reissued a "buy" rating and issued a $13.00 target price on shares of Evolus in a research report on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.50.
Get Our Latest Research Report on EOLS
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its position in shares of Evolus by 2.0% during the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company's stock valued at $784,000 after buying an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Evolus by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company's stock worth $400,000 after acquiring an additional 1,838 shares during the last quarter. Invesco Ltd. lifted its holdings in Evolus by 7.5% in the second quarter. Invesco Ltd. now owns 34,283 shares of the company's stock worth $316,000 after acquiring an additional 2,383 shares during the last quarter. California State Teachers Retirement System boosted its stake in Evolus by 79.9% in the second quarter. California State Teachers Retirement System now owns 5,455 shares of the company's stock valued at $38,000 after acquiring an additional 2,423 shares during the period. Finally, Larson Financial Group LLC boosted its stake in Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock valued at $33,000 after acquiring an additional 2,837 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.
About Evolus
(
Get Free Report)
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
